Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 5.87B 5.13B 4.74B 4.37B 8.23B 566B 8.41B 56.61B 22.27B 277B 22.06B 21.57B 954B P/E 2026 *
66.6x
P/E 2027 * 34.9x
Enterprise Value 5.87B 5.13B 4.74B 4.37B 8.23B 566B 8.41B 56.61B 22.27B 277B 22.06B 21.57B 954B EV / Sales 2026 *
20.3x
EV / Sales 2027 * 15.6x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+2.26%
1 week-4.58%
Current month-4.54%
1 month+14.67%
3 months+30.17%
6 months+53.52%
Current year+59.60%
1 week 290.2
Extreme 290.2
316.42
1 month 245
Extreme 245
326.63
Current year 175.89
Extreme 175.89
326.63
1 year 129.55
Extreme 129.55
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 66 04/12/2022
Director of Finance/CFO 47 20/05/2015
Director of Finance/CFO 56 31/10/2022
Director TitleAgeSince
Chairman 76 28/02/2003
Director/Board Member 57 26/09/2006
Director/Board Member 66 28/02/2007
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

General Counsel

15,000 0.0748%
30/06/26 Others

Chief Financial Officer

17 0.0001%
30/06/26 Others

Chief Executive Officer

132 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%-4.58%+119.34%+338.85% 5.87B
+0.74%-1.09%+54.39%+162.93% 1,043B
+1.46%-1.41%+55.45%+59.27% 602B
+0.82%+3.30%+33.89%+90.06% 449B
+0.78%-0.71%+30.04%+24.61% 327B
+1.41%+0.58%+33.92%+47.20% 279B
-0.27%-1.87%+22.13%+23.47% 264B
-1.88%+0.09%+21.94%+59.63% 201B
-1.14%+3.66%+23.69%+73.70% 169B
+0.06%+3.90%+2.17%-29.97% 143B
Average +0.34%-1.43%+39.70%+84.97% 348.29B
Weighted average by Cap. +0.49%-1.83%+40.15%+84.86%

Financials

2026 *2027 *
Net sales 290M 253M 234M 215M 406M 27.89B 415M 2.79B 1.1B 13.66B 1.09B 1.06B 47.03B 376M 328M 303M 279M 526M 36.19B 538M 3.62B 1.42B 17.72B 1.41B 1.38B 61.01B
Net income 94.48M 82.56M 76.19M 70.23M 132M 9.1B 135M 911M 358M 4.46B 355M 347M 15.34B 183M 160M 148M 136M 256M 17.63B 262M 1.76B 694M 8.63B 687M 672M 29.72B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
17/07/26 US$301.75 +1.79% 146,570
16/07/26 US$296.45 +0.06% 241,733
15/07/26 US$296.26 -1.56% 291,126
14/07/26 US$300.97 -2.68% 649,076
13/07/26 US$309.25 -2.21% 245,725
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
296.45USD
Average target price
311.30USD
Spread / Average Target
+5.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock